{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:21:52Z","timestamp":1790216512969,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijrobp.2024.09.010","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T10:09:58Z","timestamp":1725790198000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study"],"prefix":"10.1016","volume":"121","author":[{"given":"Gabriella","family":"Macchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziana","family":"Ronzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Balcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Epifani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Perrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Distefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Palluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.09.010_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0002","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0003","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0004","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0006","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0008","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0009","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0010","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0011","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"2","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijrobp.2024.09.010_bib0012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0013","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0014","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0016","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/IGC.0000000000000885","article-title":"Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer","volume":"27","author":"Laliscia","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0017","first-page":"1038","article-title":"Stereotactic body radiotherapy for lymph node relapse in Ovarian Cancer","volume":"1","author":"Trippa","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0018","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0020","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO Groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","article-title":"Koumenis C. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas","volume":"150","author":"Bi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0022","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2017.01.016","volume":"144","author":"Reiss","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0026","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"Am J Stat Assoc"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0027","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0028","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0029","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0031","doi-asserted-by":"crossref","unstructured":"Du Bois A, Sehouli J, Vergote I, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20. J. Clin. Oncol. 2020;38(15 suppl). https:\/\/doi.org\/10.1200\/JCO.2020.38. 15_suppl.6000.","DOI":"10.1200\/JCO.2020.38.15_suppl.6000"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6001","article-title":"A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\/SGOG-OV2","volume":"38","author":"Zang","year":"2020","journal-title":"J. Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0033","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2023.04.025","volume":"117","author":"Macchia","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0034","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ijgc-2021-003237","article-title":"Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2\/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2024.01.023","article-title":"Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer","volume":"184","author":"Macchia","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110072","article-title":"Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study","volume":"191","author":"Cilla","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0037","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-020-07033-7","article-title":"Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal\/pelvic lymph nodes: a retrospective study","volume":"20","author":"Ito","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0038","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ygyno.2021.12.022","article-title":"Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: a landmark analysis","volume":"164","author":"Corrigan","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.010_bib0039","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624033698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624033698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:18:12Z","timestamp":1736965092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624033698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0360301624033698"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.010","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}